We use cookies for a better user experience. Read our Privacy Policy

I Agree

Albumin (as Excipient) Market

Albumin (as Excipient) Market (Product Type: Human Serum Albumin and Recombinant Albumin; and Application: Human Serum Albumin and Recombinant Albumin) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Global Albumin (as Excipient) Market Outlook 2031

  • The global albumin (as excipient) market was valued at US$ 0.81 Bn in 2021
  • The global market is projected to grow at a CAGR of 6.3% from 2022 to 2031
  • The global albumin (as excipient) market is anticipated to reach more than US$ 1.7 Bn by the end of 2031

Analysts’ Viewpoint on Albumin (as Excipient) Market Scenario

Rise in number of pharmaceutical & biotechnology companies and growth in usage of albumin in vaccine production are driving the global albumin (as excipient) market. Albumin is used in the development of COVID-19 vaccines due to its ability to guard against shear stress, prevent surface adsorption, and provide thermal stability. Human serum albumin is commonly used in drug delivery, drug development, and vaccine production. However, there has been a shift in preference for recombinant albumin since the last few years due to the guidance from regulatory authorities to eliminate or minimize the usage of animal-derived products or materials in the manufacture of protein-based therapeutics. Increase in demand for albumin (as excipient), especially in countries in Asia such as China and India, is augmenting the global market.

albumin as excipient market

Overview of Albumin (as Excipient) Market

Albumin is commonly used in drug formulation, drug delivery, vaccines, and medical device coating. It is also commonly used in diagnostics and in vitro fertilization. Furthermore, it is used as culture medium and stabilizer. Albumin is widely used as a drug carrier in systems such as high albumin globular protein, albumin-drug nanoparticles, and pro-drugs. It is also used as a drug carrier for the treatment of various diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis. Albumin has the ability to bind to an extraordinarily diverse range of molecules, as it provides a depository for various compounds. This renders albumin ideal for usage as an excipient in vaccine and drug production.

Human serum albumin and recombinant albumin are the two types of albumin used as an excipient. Human serum albumin constitutes about 50% of human plasma protein and occurs naturally in the liver. It is proven to be an ideal stabilizer in pharmaceutical and biotech products. It is effective as a drug delivery vehicle, preferred for artificial media, and quite useful in cryopreservation and cell culture. Albumin test checks the albumin level in the blood. Low albumin or high albumin levels indicate issues with liver and kidney. The global albumin (as excipient) market is primarily driven by the increase in usage of albumin as a multifunctional excipient, rise in research & development activities, and launch of new products.

Request a sample to get extensive insights into the Albumin (as Excipient) Market

Increase in Usage of Albumin as Multifunctional Excipient to Drive Global Market

Albumin is a globular protein that is abundant in blood. It is necessary for blood osmotic pressure regulation. It protects globular proteins from oxidation by acting as a powerful antioxidant that prevents protein therapeutics from being modified. Albumin also acts as a blocking agent to prevent non-specific adsorption to glass & plastic surfaces and prevents aggregation of protein products during manufacture and delivery. Albumin has been used as a drug carrier in various systems including albumin fusion proteins, albumin-drug nanoparticles, and pro-drugs. It has also been used as a drug carrier to treat diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis.

Beneficial Properties of Human Serum Albumin to Create Lucrative Opportunities for Market Players

In terms of product type, the human serum albumin segment accounted for significant share of the market in 2021. Human serum albumin (HSA) is a highly stable protein. The stability of albumin makes its handling and storage easier compared to typical globular proteins. The surface-active character of albumin makes it an ideal candidate to be used as a surfactant to prevent protein aggregation. It also has a high glass transition temperature and amphiphilic nature, which makes it an ideal excipient for cryoprotection. Launch of new products by key players is boosting the global market. In May 2020, Bio Products Laboratory (BPL) launched ALBUMINEX 5% and ALBUMINEX 25% for the treatment of hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome (ARDS), and cardiopulmonary bypass.

Request a custom report on Albumin (as Excipient) Market

Significant Usage of Human Serum Albumin Augmenting Drug Delivery Segment

Based on application, the drug delivery segment held major share of the global albumin (as excipient) market in 2021. Human serum albumin is a better carrier in drug delivery systems due to properties such as multiple ligand binding capacity, nontoxicity, and biodegradable non-immunogenic nature. This is likely to propel the segment during the forecast period. The vaccines segment is driven by a shift toward the usage of recombinant albumin among vaccine manufacturers.

Rise in Prevalence of Liver and Kidney Diseases to Drive Pharmaceutical & Biotechnology Industry Segment

In terms of end-user, the pharmaceutical & biotechnology industry segment is projected to account for major share of the global albumin (as excipient) market during the forecast period. Growth of the segment can be ascribed to the increase in demand for advanced medications due to the rise in prevalence of chronic diseases such as liver and kidney diseases. Surge in acceptance of human serum albumin (HSA) and recombinant albumin for drug formulation, vaccine production, and culture media preparation is also anticipated to propel the pharmaceutical & biotechnology industry segment during the forecast period.

Regional Outlook of Global Albumin (as Excipient) Market

North America held the largest share of around 38% of the global albumin (as excipient) market in 2021. It is expected to be a highly lucrative region of the global market during the forecast period. North America's dominance of the global albumin (as excipient) market can be ascribed to the rise in prevalence of major chronic diseases along with the rapid increase in geriatric population in the region. The U.S. dominated the market in North America owing to the increase in demand for albumin in clinical research activities, rise in focus on non-therapeutic applications of albumin, and surge in manufacture of immunoglobulin in the country. Additionally, presence of key players and early adoption of technologically advanced products are projected to drive the market in the country.

Asia Pacific is anticipated to be the fastest growing region of the global albumin (as excipient) market during the forecast period. Aging population, increase in healthcare expenditure, and surge in competition in albumin manufacturing in countries such as China, Japan, and Australia are expected to propel the albumin (as excipient) market in the region.

Analysis of Key Players in Global Albumin (as Excipient) Market

The global albumin (as excipient) market is consolidated, with the presence of a small number of leading players. Most of the companies are investing significantly in research & development activities, primarily to introduce innovative albumin-based products for the treatment of chronic diseases. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the key players in the global albumin (as excipient) market. Albumedix Ltd., Albumin Therapeutics, LLC (Albumin Bioscience), Biotest AG, CSL Behring (CSL), Grifols, S.A, HiMedia Laboratories, InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, Sigma-Aldrich Co. (Merck KGaA), and Takeda Pharmaceutical Company Limited (Shire) are the key players operating in the global market.

Key Developments in Global Albumin (as Excipient) Market

  • In July 2021, Grifols, a global leader in the production of plasma-derived medicines, partnered with the U.S.-based company ImmunoTek Bio Centers LLC to build plasma centers
  • In July 2020, Grifols announced an agreement to acquire GC Pharma Group, a biotechnology pioneer in South Korea with a plasma fractionation facility, for around US$ 460 Mn
  • In May 2020, Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, introduced ALBUMINEX 5 percent (human albumin) solution and ALBUMINEX 25 percent for the treatment of hypovolemia, ascites, and hypoalbuminemia

Each of these players has been profiled in the albumin (as excipient) market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Albumin (as Excipient) Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 0.81 Bn

Market Forecast Value in 2031

More than US$ 1.7 Bn

Growth Rate (CAGR)

6.3%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Mn for Value & Kg for Volume

Market Analysis

It includes segment analysis well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product Type
    • Human Serum Albumin
    • Recombinant Albumin
  • Application
    • Human Serum Albumin
      • Drug Formulation
      • Drug Delivery
      • Vaccines
      • Medical Device Coating
      • Culture Medium & Stabilizer
      • Diagnostics
      • In Vitro Fertilization
    • Recombinant Albumin
      • Drug Formulation
      • Drug Delivery
      • Vaccines
      • Medical Device Coating
      • Culture Medium & Stabilizer
      • Diagnostics
      • In Vitro Fertilization
  • End-user
    • Pharmaceutical & Biotechnology Industry
    • Research Institutes
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Albumedix Ltd.
  • Albumin Therapeutics, LLC (Albumin Bioscience)
  • Biotest AG
  • CSL Behring (CSL)
  • Grifols, S.A.
  • HiMedia Laboratories
  • InVitria
  • Medxbio Pte Ltd.
  • Octapharma AG
  • RayBiotech, Inc.
  • SeraCare Life Sciences
  • Sigma-Aldrich Co. (Merck KGaA)
  • Takeda Pharmaceutical Company Limited (Shire)

Customization Scope

Available upon request

Pricing

Available upon request

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global albumin (as excipient) market in 2021?

The global albumin (as excipient) market was valued at US$ 0.81 Bn in 2021.

How big will be the global albumin (as excipient) market in 2031?

The global albumin (as excipient) market is projected to reach more than US$ 1.7 Bn by 2031.

What will be the CAGR of the global albumin (as excipient) market during the forecast period (2022–2031)?

The global albumin (as excipient) market is anticipated to grow at a CAGR of 6.3% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in usage of albumin as multifunctional excipient is expected to drive the global albumin (as excipient) market.

Which region will account for the major share of the global market during the forecast period?

North America is likely to account for major share of the global albumin (as excipient) market during the forecast period.

Who are the prominent players in the global albumin (as excipient) market?

Prominent players in the global albumin (as excipient) market include Albumedix Ltd., Albumin Therapeutics, LLC (Albumin Bioscience), Biotest AG, CSL Behring (CSL), Grifols, S.A, HiMedia Laboratories, InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, Sigma-Aldrich Co. (Merck KGaA) and Takeda Pharmaceutical Company Limited (Shire).

1. Preface

    1.1. Report Scope and Market Segmentation

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions and Acronyms Used

    2.2. Research Methodology

3. Executive Summary

4. Market Overview

    4.1. Introduction

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunity

    4.3. Global Albumin (as Excipient) Market Forecast

    4.4. Global Albumin (as Excipient) Market Outlook

5. Market Outlook

    5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

    5.2. Technological Advancement

    5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Albumin (as Excipient) Market Analysis and Forecast, by Product Type

    6.1. Global Albumin (as Excipient) Market Analysis and Forecast, by Product Type

    6.2. Introduction

    6.3. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type

    6.4. Global Albumin (as Excipient) Market Forecast, by Product Type

        6.4.1. Human Serum Albumin

        6.4.2. Recombinant Albumin

    6.5. Global Albumin (as Excipient) Market Analysis, by Product Type

7. Global Albumin (as Excipient) Market Analysis and Forecast, by Application

    7.1. Introduction

    7.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application

    7.3. Global Albumin (as Excipient) Market Forecast, by Application

        7.3.1. Human Serum Albumin Applications

            7.3.1.1. Drug Formulation

            7.3.1.2. Drug Delivery

            7.3.1.3. Vaccines

            7.3.1.4. Medical Device Coating

            7.3.1.5. Culture Medium & Stabilizer

            7.3.1.6. Diagnostics

            7.3.1.7. In Vitro Fertilization

        7.3.2. Recombinant Albumin

            7.3.2.1. Drug Formulation

            7.3.2.2. Drug Delivery

            7.3.2.3. Vaccines

            7.3.2.4. Medical Device Coating

            7.3.2.5. Culture Medium & Stabilizer

            7.3.2.6. Diagnostics

            7.3.2.7. In Vitro Fertilization

    7.4. Global Albumin (as Excipient) Market Analysis, by Application

8. Global Albumin (as Excipient) Market Analysis and Forecast, by End-user

    8.1. Introduction

    8.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user

    8.3. Global Albumin (as Excipient) Market Forecast, by End-user

        8.3.1. Pharmaceutical & Biotechnology Industry

        8.3.2. Research Institutes

        8.3.3. Others

    8.4. Global Albumin (as Excipient) Market Analysis, by End-user

9. Global Albumin (as Excipient) Market Analysis and Forecast, by Region

    9.1. Global Albumin (as Excipient) Market Analysis, by Region

    9.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Region

    9.3. Global Albumin (as Excipient) Market Forecast, by Region

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East & Africa

10. North America Albumin (as Excipient) Market Analysis

    10.1. North America Albumin (as Excipient) Market Overview

    10.2. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Country

    10.3. North America Albumin (as Excipient) Market Forecast, by Country

        10.3.1. U.S.

        10.3.2. Canada

    10.4. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type

    10.5. North America Albumin (as Excipient) Market Forecast, by Product Type

        10.5.1. Human Serum Albumin

        10.5.2. Recombinant Albumin

    10.6. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application

    10.7. North America Albumin (as Excipient) Market Forecast, by Application

        10.7.1. Human Serum Albumin Applications

            10.7.1.1. Drug Formulation

            10.7.1.2. Drug Delivery

            10.7.1.3. Vaccines

            10.7.1.4. Medical Device Coating

            10.7.1.5. Culture Medium & Stabilizer

            10.7.1.6. Diagnostics

            10.7.1.7. In Vitro Fertilization

        10.7.2. Recombinant Albumin

            10.7.2.1. Drug Formulation

            10.7.2.2. Drug Delivery

            10.7.2.3. Vaccines

            10.7.2.4. Medical Device Coating

            10.7.2.5. Culture Medium & Stabilizer

            10.7.2.6. Diagnostics

            10.7.2.7. In Vitro Fertilization

    10.8. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user

    10.9. North America Albumin (as Excipient) Market Forecast, by End-user

        10.9.1. Pharmaceutical & Biotechnology Industry

        10.9.2. Research Institutes

        10.9.3. Others

11. Europe Albumin (as Excipient) Market Analysis

    11.1. Europe Albumin (as Excipient) Market Overview

    11.2. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region

    11.3. Europe Albumin (as Excipient) Market Forecast, by Countries/Sub-region

        11.3.1. Germany

        11.3.2. France

        11.3.3. U.K.

        11.3.4. Italy

        11.3.5. Spain

        11.3.6. Rest of Europe

    11.4. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type

    11.5. Europe Albumin (as Excipient) Market Forecast, by Product Type

        11.5.1. Human Serum Albumin

        11.5.2. Recombinant Albumin

    11.6. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application

    11.7. Europe Albumin (as Excipient) Market Forecast, by Application

        11.7.1. Human Serum Albumin Applications

            11.7.1.1. Drug Formulation

            11.7.1.2. Drug Delivery

            11.7.1.3. Vaccines

            11.7.1.4. Medical Device Coating

            11.7.1.5. Culture Medium & Stabilizer

            11.7.1.6. Diagnostics

            11.7.1.7. In Vitro Fertilization

        11.7.2. Recombinant Albumin

            11.7.2.1. Drug Formulation

            11.7.2.2. Drug Delivery

            11.7.2.3. Vaccines

            11.7.2.4. Medical Device Coating

            11.7.2.5. Culture Medium & Stabilizer

            11.7.2.6. Diagnostics

            11.7.2.7. In Vitro Fertilization

    11.8. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user

    11.9. Europe Albumin (as Excipient) Market Forecast, by End-user

        11.9.1. Pharmaceutical & Biotechnology Industry

        11.9.2. Research Institutes

        11.9.3. Others

12. Asia Pacific Albumin (as Excipient) Market Analysis

    12.1. Asia Pacific Albumin (as Excipient) Market Overview

    12.2. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region

    12.3. Asia Pacific Albumin (as Excipient) Market Forecast, by Countries/Sub-region

        12.3.1. Japan

        12.3.2. China

        12.3.3. India

        12.3.4. Australia & New Zealand

        12.3.5. Rest of Asia Pacific

    12.4. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type

    12.5. Asia Pacific Albumin (as Excipient) Market Forecast, by Product Type

        12.5.1. Human Serum Albumin

        12.5.2. Recombinant Albumin

    12.6. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application

    12.7. Asia Pacific Albumin (as Excipient) Market Forecast, by Application

        12.7.1. Human Serum Albumin Applications

            12.7.1.1. Drug Formulation

            12.7.1.2. Drug Delivery

            12.7.1.3. Vaccines

            12.7.1.4. Medical Device Coating

            12.7.1.5. Culture Medium & Stabilizer

            12.7.1.6. Diagnostics

            12.7.1.7. In Vitro Fertilization

        12.7.2. Recombinant Albumin

            12.7.2.1. Drug Formulation

            12.7.2.2. Drug Delivery

            12.7.2.3. Vaccines

            12.7.2.4. Medical Device Coating

            12.7.2.5. Culture Medium & Stabilizer

            12.7.2.6. Diagnostics

            12.7.2.7. In Vitro Fertilization

    12.8. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user

    12.9. Asia Pacific Albumin (as Excipient) Market Forecast, by End-user

        12.9.1. Pharmaceutical & Biotechnology Industry

        12.9.2. Research Institutes

        12.9.3. Others

13. Latin America Albumin (as Excipient) Market Analysis

    13.1. Latin America Albumin (as Excipient) Market Overview

    13.2. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region

    13.3. Latin America Albumin (as Excipient) Market Forecast, by Countries/Sub-region

        13.3.1. Brazil

        13.3.2. Mexico

        13.3.3. Rest of Latin America

    13.4. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type

    13.5. Latin America Albumin (as Excipient) Market Forecast, by Product Type

        13.5.1. Human Serum Albumin

        13.5.2. Recombinant Albumin

    13.6. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application

    13.7. Latin America Albumin (as Excipient) Market Forecast, by Application

        13.7.1. Human Serum Albumin Applications

            13.7.1.1. Drug Formulation

            13.7.1.2. Drug Delivery

            13.7.1.3. Vaccines

            13.7.1.4. Medical Device Coating

            13.7.1.5. Culture Medium & Stabilizer

            13.7.1.6. Diagnostics

            13.7.1.7. In Vitro Fertilization

        13.7.2. Recombinant Albumin

            13.7.2.1. Drug Formulation

            13.7.2.2. Drug Delivery

            13.7.2.3. Vaccines

            13.7.2.4. Medical Device Coating

            13.7.2.5. Culture Medium & Stabilizer

            13.7.2.6. Diagnostics

            13.7.2.7. In Vitro Fertilization

    13.8. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user

    13.9. Latin America Albumin (as Excipient) Market Forecast, by End-user

        13.9.1. Pharmaceutical & Biotechnology Industry

        13.9.2. Research Institutes

        13.9.3. Others

14. Middle East & Africa Albumin (as Excipient) Market Analysis

    14.1. Middle East & Africa Albumin (as Excipient) Market Overview

    14.2. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region

    14.3. Middle East & Africa Albumin (as Excipient) Market Forecast, by Countries/Sub-region

        14.3.1. GCC Countries

        14.3.2. South Africa

        14.3.3. Rest of MEA

    14.4. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type

    14.5. Middle East & Africa Albumin (as Excipient) Market Forecast, by Product Type

        14.5.1. Human Serum Albumin

        14.5.2. Recombinant Albumin

    14.6. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application

    14.7. Middle East & Africa Albumin (as Excipient) Market Forecast, by Application

        14.7.1. Human Serum Albumin Applications

            14.7.1.1. Drug Formulation

            14.7.1.2. Drug Delivery

            14.7.1.3. Vaccines

            14.7.1.4. Medical Device Coating

            14.7.1.5. Culture Medium & Stabilizer

            14.7.1.6. Diagnostics

            14.7.1.7. In Vitro Fertilization

        14.7.2. Recombinant Albumin

            14.7.2.1. Drug Formulation

            14.7.2.2. Drug Delivery

            14.7.2.3. Vaccines

            14.7.2.4. Medical Device Coating

            14.7.2.5. Culture Medium & Stabilizer

            14.7.2.6. Diagnostics

            14.7.2.7. In Vitro Fertilization

    14.8. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user

    14.9. Middle East & Africa Albumin (as Excipient) Market Forecast, by End-user

        14.9.1. Pharmaceutical & Biotechnology Industry

        14.9.2. Research Institutes

        14.9.3. Others

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis/Ranking, by Company, 2021

    15.3. Company Profiles

        15.3.1. Albumedix Ltd.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Product Portfolio

            15.3.1.3. Financial Overview

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. Albumin Therapeutics, LLC (Albumin Bioscience)

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Product Portfolio

            15.3.2.3. Financial Overview

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. Biotest AG

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Product Portfolio

            15.3.3.3. Financial Overview

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. CSL Behring (CSL)

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Product Portfolio

            15.3.4.3. Financial Overview

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Grifols, S.A.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Product Portfolio

            15.3.5.3. Financial Overview

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. HiMedia Laboratories

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Product Portfolio

            15.3.6.3. Financial Overview

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. InVitria

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Product Portfolio

            15.3.7.3. Financial Overview

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Medxbio Pte Ltd

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Product Portfolio

            15.3.8.3. Financial Overview

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Octapharma AG

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Product Portfolio

            15.3.9.3. Financial Overview

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview

        15.3.10. RayBiotech, Inc.

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Product Portfolio

            15.3.10.3. Financial Overview

            15.3.10.4. SWOT Analysis

            15.3.10.5. Strategic Overview

        15.3.11. SeraCare Life Sciences

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Product Portfolio

            15.3.11.3. Financial Overview

            15.3.11.4. SWOT Analysis

            15.3.11.5. Strategic Overview

        15.3.12. Sigma-Aldrich Co. (Merck KGaA)

            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.12.2. Product Portfolio

            15.3.12.3. Financial Overview

            15.3.12.4. SWOT Analysis

            15.3.12.5. Strategic Overview

        15.3.13. Takeda Pharmaceutical Company Limited (Shire)

            15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.13.2. Product Portfolio

            15.3.13.3. Financial Overview

            15.3.13.4. SWOT Analysis

            15.3.13.5. Strategic Overview

List of Tables

Table 01: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 02: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 03: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 04: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Application, 2017–2031

Table 05: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 06: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 07: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 08: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 09: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 10: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 11: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Region, 2017–2031

Table 12: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 14: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 15: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 16: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 17: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 18: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 19: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 20: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 23: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 24: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 25: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 26: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 27: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 28: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 29: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 30: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 31: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 32: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 33: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 34: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 35: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 36: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 37: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 38: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 39: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 40: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 41: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 42: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 43: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 44: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 45: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 46: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 47: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 48: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 49: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031

Table 50: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 51: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031

Table 52: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 53: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031

Table 54: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 55: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031

Table 56: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Albumin (as Excipient) Market Volume (Kg) Forecast, 2017–2031

Figure 03: Global Albumin (as Excipient) Market Value Share, by Product Type, 2021

Figure 04: Global Albumin (as Excipient) Market Value Share, by End-user, 2021

Figure 05: Global Albumin (as Excipient) Market Value Share, by Application (Human Serum Albumin Applications) (2021)

Figure 06: Global Albumin (as Excipient) Market Value Share, by Region, 2021

Figure 07: Global Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031

Figure 08: Global Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031

Figure 09: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Human Serum Albumin, 2017–2031

Figure 10: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Recombinant Albumin, 2017–2031

Figure 11: Global Albumin (as Excipient) Market Value Share Analysis, by Application, 2021 and 2031

Figure 12: Global Albumin (as Excipient) Market Attractiveness, by Application, 2022–2031

Figure 13: Global Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031

Figure 14: Global Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031

Figure 15: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Drug Formulation, 2017–2031

Figure 16: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Drug Delivery, 2017–2031

Figure 17: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Vaccines, 2017–2031

Figure 18: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Medical Device Coating, 2017–2031

Figure 19: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Culture Medium & Stabilizer, 2017–2031

Figure 20: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Diagnostics, 2017–2031

Figure 21: Global Albumin (as Excipient) Market Revenue (US$ Mn), by In Vitro Fertilization, 2017–2031

Figure 22: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Drug Formulation, 2017–2031

Figure 23: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Drug Delivery, 2017–2031

Figure 24: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Vaccines, 2017–2031

Figure 25: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Medical Device Coating, 2017–2031

Figure 26: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Culture Medium & Stabilizer, 2017–2031

Figure 27: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Diagnostics, 2017–2031

Figure 28: Global Albumin (as Excipient) Market Revenue (US$ Mn), by In Vitro Fertilization, 2017–2031

Figure 29: Global Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031

Figure 30: Global Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031

Figure 31: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Industry, 2017–2031

Figure 32: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Specialty Centers, 2017–2031

Figure 33: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Others, 2017–2031

Figure 34: Global Albumin (as Excipient) Market Value Share Analysis, by Region, 2021 and 2031

Figure 35: Global Albumin (as Excipient) Market Attractiveness, by Region, 2022-2031

Figure 36: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 37: North America Albumin (as Excipient) Market Value Share (%), by Country, 2021 and 2031

Figure 38: North America Albumin (as Excipient) Market Attractiveness, by Country, 2022–2031

Figure 39: North America Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031

Figure 40: North America Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031

Figure 41: North America Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031

Figure 42: North America Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031

Figure 43: North America Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031

Figure 44: North America Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031

Figure 45: North America Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031

Figure 46: North America Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031

Figure 47: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 48: Europe Albumin (as Excipient) Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 49: Europe Albumin (as Excipient) Market Attractiveness, by Country/Sub-region, 2022–2031

Figure 50: Europe Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031

Figure 51: Europe Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031

Figure 52: Europe Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031

Figure 53: Europe Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031

Figure 54: Europe Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031

Figure 55: Europe Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031

Figure 56: Europe Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031

Figure 57: Europe Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031

Figure 58: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 59: Asia Pacific Albumin (as Excipient) Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 60: Asia Pacific Albumin (as Excipient) Market Attractiveness, by Country/Sub-region, 2022–2031

Figure 61: Asia Pacific Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031

Figure 62: Asia Pacific Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031

Figure 63: Asia Pacific Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031

Figure 64: Asia Pacific Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031

Figure 65: Asia Pacific Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031

Figure 66: Asia Pacific Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031

Figure 67: Asia Pacific Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031

Figure 68: Asia Pacific Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031

Figure 69: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 70: Latin America Albumin (as Excipient) Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 71: Latin America Albumin (as Excipient) Market Attractiveness, by Country/Sub-region, 2022–2031

Figure 72: Latin America Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031

Figure 73: Latin America Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031

Figure 74: Latin America Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031

Figure 75: Latin America Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031

Figure 76: Latin America Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031

Figure 77: Latin America Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031

Figure 78: Latin America Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031

Figure 79: Latin America Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031

Figure 80: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 81: Middle East & Africa Albumin (as Excipient) Market Value Share (%), by Country/Sub-region, 2021 and 2031

Figure 82: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by Country/Sub-region, 2022–2031

Figure 83: Middle East & Africa Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031

Figure 84: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031

Figure 85: Middle East & Africa Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031

Figure 86: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031

Figure 87: Middle East & Africa Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031

Figure 88: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031

Figure 89: Middle East & Africa Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031

Figure 90: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031

Figure 91: Global Albumin (as Excipient) Market Share, by Company, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

540

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved